Anti-IgE Monoclonal Antibody (Omalizumab) is effective in Treating Bullous Pemphigoid and Its Effects on Soluble CD200

Yalcin A. D., Genc G. E., Celik B., GÜMÜŞLÜ S.

CLINICAL LABORATORY, vol.60, no.3, pp.523-524, 2014 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Letter
  • Volume: 60 Issue: 3
  • Publication Date: 2014
  • Doi Number: 10.7754/clin.lab.2013.130642
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.523-524
  • Keywords: Omalizumab, Bullous Pemphigoid, Anti-IgE monoclonal antibody
  • Akdeniz University Affiliated: Yes


Herein, we report a case of a man with pruritic bullous pemphigoid (BP) and very high levels of total IgE (5000 kU/L) who was refractory to standard aggressive immunosuppressive regimens (systemic steroids, daily cyclophosphamide) for BP but responded rapidly to systemic anti-IgE (omalizumab). Our patient is a 28 year-old white male. On admission 70% of his body surface area was involved with large bullae overlying urticarial plaques, involving his upper and lower extremities, chest, and abdomen. The circulating level of sCD200 was 48.45 pg/mL in serum and 243 pg/mL in blister fluid. During the second month of follow-up, the patient's sCD200 level decreased to 26.7 pg/mL. After the second round of omalizumab (300 mg), frequency of exacerbations decreased and after the 13th round it had completely disappeared.